[Experimental studies with Bergenia purpurascens, the frequency of micronucleus in NIH mice, the frequency of SCE, and chromosome aberration in human lymphocytes].

Bergenia purpurascens tablets were prepared according to the technological requirements of Chinese traditional medicine. Using these tablets to treat patients with esophageal epithelial cell proliferation and inflammation for five years in Lang Zhong and Yan Ting Counties, Sichuan Province, a cure rate of 88.7% was achieved, demonstrating that Bergenia purpurascens is a new and promising drug. However, in order to determine whether or not long period of administration will induce mutagenesis carcinogenesis, we carried out micronucleus, chromosomal aberration and sister chromatid exchange frequency tests. The results showed that the drug neither induces micronucleus formation nor chromosomal aberration and SCE. Therefore, we conclude that this drug is safe and without toxic side effects.